4-PBA, which is FDA-approved for the treatment of urea cycle disorders since the 1980s, has shown great merit in recouping disease variants of hCRT1 (El-Kasaby et al., 2019) and hGAT1 (Kasture et al., 2023). Here, SLC6A1 is linked to urea cycle disorder.